Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis
Thi Lien-Anh Nguyên(Jewish General Hospital), John Hiscott(Istituto Pasteur), Jean‐Simon Diallo(University of Ottawa), Harold Atkins(University of Ottawa), Markus Vähä‐Koskela(University of Helsinki), Caroline J. Breitbach(University of Ottawa), Joel Werier(University of Ottawa), Barbara C. Vanderhyden(University of Ottawa), Simon Léveillé(Jewish General Hospital), Theresa Falls(Ottawa Hospital), John C. Bell(Ottawa Hospital), Amber Yasmeen(Jewish General Hospital), David F. Stojdl(Ottawa Regional Cancer Foundation), Valerie E. Snoulten(University of Ottawa), Hesham Abdelbary(University of Ottawa), David H. Kirn(Alameda Applied Sciences Corporation (United States)), Meztli Arguello(McGill University), Tarek A. Bismar(University of Calgary)
Cited by 182
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Hostile takeovers: viral appropriation of the NF-kB pathway
|Journal of Clinical Investigation|2001|606
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
|The Lancet Oncology|2008|522
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
|Journal of Computer Assisted Tomography|1980|503